We estimate that the initial public offering price will be between $10.00 and $12.00 per share.Our common stock has been approved for listing on The NASDAQ Global Market under the symbol “CNAT.”We are an “emerging growth company” as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to
Any representation to the contrary is a criminal offense.StifelPiper JaffrayJMP SecuritiesSunTrust Robinson HumphreyThe date of this prospectus is, 2013.Table of ContentsTABLE OF CONTENTSPageProspectus Summary1Risk Factors9Special Note Regarding Forward-Looking Statements38Use of Proceeds39Dividend Policy40Capitalization41Dilution43Selected Consolidated Financial Data45Management’s Discussion and Analysis of Financial Condition and Results of Operations47Business62Management91Executive and Director Compensation100Certain Relationships and Related Person Transactions121Principal Stockholders126Description of Capital Stock131Shares Eligible for Future Sale136Material United States Federal Income Tax Consequences to Non-U.S. Holders of Common Stock139Underwriting143Legal Matters150Experts150Where You Can Find More Information150Index to Financial StatementsF-1Until             , 2013 (25 days after the commencement of this
trials or limit the commercial profile of emricasan.3Table of Contents•Clinical drug development involves uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results.•The FDA regulatory approval process is lengthy and time-consuming, and if we experience significant delays in the clinical development and
out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize emricasan and our business could be substantially harmed.•We have a limited operating history, have incurred significant operating losses since our inception, including an accumulated deficit of $61.1
million as of March 31, 2013, and anticipate that we will continue to incur losses for the foreseeable future.•We have not generated any revenues to date from product sales, and we may never achieve or sustain profitability.•If we fail to obtain additional financing, we may be unable to complete the development and commercialization of emricasan.•If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to
As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.4Table of ContentsTHE OFFERINGCommon stock offered by us5,000,000 shares (or 5,750,000 shares if the underwriters exercise their option to purchase additional shares in full)Common stock to be outstanding after this offering14,575,485 shares (or 15,325,485 shares if the underwriters exercise their option to purchase additional shares in full)Use of proceedsWe intend to use the net proceeds of this offering to fund the clinical development of emricasan and for working capital and general corporate purposes.
interest thereon) that we issued to Pfizer Inc. in July 2010, at a price per share equal to the fair market value of our common stock on the date of conversion.Unless otherwise indicated, this prospectus reflects and assumes the following:•the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, which will occur
calculate the historical and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts.7Table of ContentsAs of March 31, 2013ActualProForma(1)Pro Forma AsAdjusted(1)(2)(unaudited)Consolidated Balance Sheet Data:Cash, cash equivalents and short-term investments$5,095,4867,059,13455,809,134Working capital4,438,0006,401,64855,151,648Total assets5,246,0207,209,66855,959,668Convertible preferred stock warrant liability707,509——Note payable1,000,0001,000,0001,000,000Long-term debt—842,418842,418Convertible preferred stock63,908,372——Total stockholders’ (deficit) equity(61,110,679)4,626,32153,376,321(1)Gives effect to:•the issuance of $1.0 million in aggregate principal amount of 2013 Notes in May 2013 and the automatic conversion of the 2013 Notes (including
of future clinical trial results may result in our failure to obtain regulatory approval to market emricasan, which would significantly harm our business, prospects, financial condition and results of operations.
for commercialization, its acceptance will depend on a number of factors, including:•the clinical indications for which emricasan is approved;•physicians, major operators of tertiary care centers and transplant centers and patients considering emricasan as a safe and effective treatment;•the potential and perceived advantages of emricasan over alternative treatments;•the prevalence and severity of any side effects;•product labeling or product insert requirements of the FDA or other regulatory authorities;•the timing of market introduction of emricasan as well as competitive products;•the cost of treatment in relation to alternative treatments;•the availability of adequate reimbursement and pricing by third-party payors and government authorities;•relative convenience and ease of administration; and•the effectiveness of our sales and marketing efforts.If emricasan is approved but fails to achieve market acceptance among physicians, patients or others in the medical community,
we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.Coverage and reimbursement may be limited or unavailable in certain market segments for emricasan, which could make it
companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:•the demand for emricasan, if we obtain regulatory approval;•our ability to set a price that we believe is fair for our products;•our ability to generate revenues and achieve or maintain profitability;•the level of taxes that we are required to pay; and•the availability of capital.Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from
Regardless of the merits or eventual outcome, liability claims may result in:•decreased demand for emricasan;•injury to our reputation;•withdrawal of clinical trial participants;•initiation of investigations by regulators;•costs to defend the related litigation;•a diversion of management’s time and our resources;•substantial monetary awards to trial participants or patients;•product recalls, withdrawals or labeling, marketing or promotional restrictions;•loss of revenue;•exhaustion of any available insurance and our capital resources;•the inability to commercialize emricasan; and•a decline in our share price.Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential
facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all, which would significantly impact our ability to develop, obtain regulatory approval for or market emricasan.In addition, the manufacture of pharmaceutical products is complex and requires significant expertise and capital
profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.If we fail to obtain additional financing, we may be unable to complete the development and commercialization of
regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information;•adverse results or delays in clinical trials;•our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;•adverse regulatory decisions, including failure to receive regulatory approval for emricasan;•changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;•adverse developments concerning our manufacturers;•our inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;•our inability to establish collaborations if needed;31Table of Contents•our failure to commercialize emricasan;•additions or departures of key scientific or management personnel;•unanticipated serious safety concerns related to the use of emricasan;•introduction of new products or services offered by us or our competitors;•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;•our ability to effectively manage our growth;•the size and growth, if any, of the ACLF, CLF and HCV-POLT markets and other targeted markets;•our ability to successfully enter new markets;•actual or anticipated variations in quarterly operating results;•our cash position;•our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;•publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities